Menu

Recent Interviews

Matthew Salthouse, CEO, Kainantu Resources

Matthew Salthouse
CEO | Kainantu Resources
3 Phillip Street #19-01 Royal Group Building, 048693 Singapore (SGP)

info@krl.com.sg

+65 6920 2020

Interview Kainantu Resources: "We hold the key to growth in the Asia-Pacific region".


Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

info@troilusgold.com

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".


John Jeffrey, CEO, Saturn Oil + Gas Inc.

John Jeffrey
CEO | Saturn Oil + Gas Inc.
Suite 1000 - 207 9 Ave SW, T2P 1K3 Calgary (CAN)

info@saturnoil.com

+1-587-392-7900

Saturn Oil + Gas CEO John Jeffrey: "Acquisition has increased production by 2,000%"


26. August 2021 | 10:41 CET

BioNTech, Cardiol Therapeutics, Bayer: Where Covid-19 still provides returns

  • Biotechnology
Photo credits: pixabay.com

The pandemic has not only brought losers. There is also a long list of winners. Starting with Amazon and Deutsche Post and ending with BioNTech. Before Corona, the latter Company was always considered a beacon of hope around mRNA technology. Then came the pandemic, and suddenly several small test balloons turned into a gigantic project as we know it today, with a successful outcome. We shed light on BioNTech and also focus on other potential winners of the pandemic.

time to read: 3 minutes by Nico Popp
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , CARDIOL THERAPEUTICS | CA14161Y2006 , BAYER AG NA O.N. | DE000BAY0017


 

Author

Nico Popp

At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

About the author


BioNTech: What is next?

Currently, BioNTech is investigating the potential of a third vaccination. While advocates of a global approach to vaccination call for Western industrialized countries to forgo the third dose in favor of the first dose in poorer countries, tangible benefits of such a "booster vaccination" are emerging. Given existing supply contracts and public pressure, BioNTech could soon be shipping boosters. Initial studies on the effectiveness of the boosters are promising. Another positive for BioNTech is that the vaccine has received full approval from the US Food and Drug Administration (FDA). That means that even the last minor reservations about the vaccine have been dispelled. Many employers and even official bodies are now likely to urge their employees to be vaccinated. For example, mandatory vaccination in the US military is now expected - good for business for BioNTech.

While noted US immunologist Anthony Fauci expects a return to normalcy next spring, BioNTech may be one of the companies that has benefited most from the pandemic. In addition to sales of the vaccine, BioNTech is likely to have gained confidence and capital around other projects, putting it in a much better position than it was two years ago. In a slightly different form, such a development could also be in store for Canadian pharmaceutical Company Cardiol Therapeutics, recently listed on the Nasdaq.

Cardiol Therapeutics: Nasdaq listing and FDA provide a boost

Cardiol is researching drugs for acute myocarditis. This inflammation of the heart also occurs in connection with Covid-19. In general, inflammatory processes are considered to be a driver for many different diseases. Yesterday, Cardiol Therapeutics received a positive notification from the US Food and Drug Administration (FDA): According to this, the regulator has expressed its non-objection regarding a Phase II study that will investigate the efficacy of CardiolRx and its effects on the regeneration of the heart muscle. "IND approval to proceed with our Phase II clinical trial of CardiolRx in patients with acute myocarditis represents another important milestone for Cardiol as we continue to develop new treatment options for patients with inflammatory heart disease," commented David Elsley, President and CEO of Cardiol Therapeutics.

The green light from regulators has been very well received in the market. In general, the listing on Nasdaq is good for the stock - the trend has been upwards for three weeks. The analysts at Leede Jones Gable also believe that the share has potential and see the price target for Cardiol Therapeutics at CAD 12.50 in an analysis published yesterday. The share is currently trading at just under CAD 4. In the past, biotech stocks with promising projects were often able to convert the attention thus gained into rising prices after a listing on the Nasdaq. The reason: Many funds are only allowed to invest if a company is also listed on a well-known trading venue. The Nasdaq represents an upgrade compared to the Toronto Stock Exchange and the trading centers in Germany. Cardiol Therapeutics could have one of the drugs in its portfolio that effectively treats at-risk groups when infected in the new normal - that is, when Covid-19 becomes more like the flu. In any case, the potential use in Covid-19 patients should not be detrimental to the approval process.

Bayer: Boring with qualities

One stock that is also repeatedly mentioned in connection with increased investment in the healthcare system is Bayer. After all, the chemical company has a drug division responsible for more than 40% of its sales. With its focus on cell and genetic engineering, Bayer is considered a technology leader. In addition, there is a good business with seeds. The latter is benefiting from a growing world population and rising raw material prices. In the first quarter, the Company succeeded in posting a substantial 40% jump in profits. Although the stock has been languishing for years, it looks fundamentally sound. However, there is currently a lack of momentum. To tide investors over, however, they can look forward to a dividend yield of around 3.8%.


While Bayer is a solid stock that will not offer any big surprises, the situation is quite different for BioNTech and Cardiol Therapeutics. The latter companies have future projects and potential blockbusters in their development portfolio. However, BioNTech is already the talk of the town and is valued accordingly. That leaves Cardiol, where a huge growth opportunity meets a valuation of only around EUR 95 million.


Author

Nico Popp

At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

15. September 2021 | 12:17 CET | by Nico Popp

Valneva, Cardiol Therapeutics, Sartorius: Healthy returns in every market phase

  • Biotechnology

The pandemic has given the healthcare sector a boost. If people were still somewhat hesitant to talk about the digitization of the healthcare system in 2019, the epidemic has clearly revealed where the weaknesses are. New drugs and procedures could also be tested under the new framework conditions. If nothing else, the industry is getting renewed attention as a result. We outline three companies and explain whether the shares have prospects or not.

Read

14. September 2021 | 13:10 CET | by Nico Popp

BioNTech, Defence Therapeutics, Valneva: Here, the overall market (almost) does not matter

  • Biotechnology

Is the crash coming or not? Meanwhile, even Wall Street banks are warning of an imminent crash event. Many commentators are jumping on the bandwagon. The reasons: Delta variation, supply problems and inflation, and an economy that could suffer. But if you compare the crashes of the past years, one thing becomes clear: Only the fewest price setbacks came with notice! We present three stocks that many investors believe can combine growth and security.

Read

10. September 2021 | 12:43 CET | by André Will-Laudien

NanoRepro, XPhyto Therapeutics, BioNTech, Valneva - The next biotech wave is rolling!

  • Biotechnology

So far, vaccine manufacturers can maintain their high valuation because the next wave of new infections is rolling in. In Germany, tests will be subject to fees starting in October, making public life more expensive for those who want to participate. In surveys, most German citizens have expressed support for fee-based testing; probably, the populations here should be separated into "vaccinated" and "unvaccinated" to indicate general opinion accurately. Four interesting values benefit from the current situation.

Read